Rigel Pharmaceuticals (RIGL +0.4%) says it's made clinical advancement in three programs...

|About: Rigel Pharmaceuticals, Inc. (RIGL)|By:, SA News Editor

Rigel Pharmaceuticals (RIGL +0.4%) says it's made clinical advancement in three programs currently in development. The first program is R348, a topical ophthalmic formulation of a JAK/SYK inhibitor being developed to treat dry eye disease. The company notes that the drug was well tolerated in Phase 1 trials, and it plans to initiate Phase 2 trials soon. The other two are oncology programs being conducted by corporate partners, including an AXL kinase inhibitor under development by BerGenBio AS and a ligase inhibitor by Daiichi Sankyo (DSNKY.PK).